Lilly details Medicare GLP-1 Bridge access for Zepbound and Foundayo
The CMS demonstration, which Lilly outlined on June 25, is described as a short-term expansion of GLP-1 coverage for eligible Part D beneficiaries.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 26 03:00 ETSource: quiverquant.com
The wire
- 01Lilly published additional details on June 25 for the Medicare GLP-1 Bridge program, setting out how eligible Medicare Part D patients may access Zepbound and oral Foundayo beginning July 1, 2026.
- 02Pharmacists and telehealth operators fielding Medicare questions now have a start date and a named product list for the demonstration.
- 03CMS frames the Bridge as a short-term demonstration; eligibility rules, duration and what happens to patients when it ends are not spelled out in this account, which is an AI-assisted market note.
From the source
Read at quiverquant.comEli Lilly Shares Jump as Investors Focus on Medicare GLP-1 Access and Obesity Franchise Momentum
Eli Lilly and Company (LLY) is up 5.8% today. Here is some analysis on what might have caused this price movement.